Harmony Biosciences Holdings, Inc. 8-K

What Happened
Harmony Biosciences Holdings, Inc. filed an 8-K on April 2, 2026 announcing that Peter Anastasiou was named Senior Executive Vice President and Chief Operating Officer (COO), effective April 2, 2026. In connection with the appointment, Mr. Anastasiou resigned from the Company’s Board (Class III director) effective the same date. The company also appointed Troy Ignelzi as a Class III director effective April 2, 2026 (to hold office until the 2026 annual meeting, anticipated May 14, 2026). Separately, Class III director Antonio Gracias notified the Board that he will not stand for re-election; his term ends at the start of the Annual Meeting. Harmony issued a press release on April 2, 2026 reporting these changes.

Key Details

• Employment: Harmony Biosciences Management, Inc. entered an Executive Employment Agreement with Peter Anastasiou effective April 2, 2026.
• Pay & Bonus: Annual base salary $600,000 and target annual bonus of 55% of base salary.
• Equity: Option award with aggregate grant-date fair value of $3,700,000; vests 25% on first anniversary, then quarterly through year four, subject to continued service.
• Severance & Benefits: If terminated without cause or for good reason, Mr. Anastasiou is eligible for (i) cash severance equal to one year’s base salary paid over 12 months, (ii) 12 months of subsidized healthcare, (iii) partial or 12‑month accelerated vesting of option shares depending on timing, and (iv) up to 12 months of company-paid outplacement; enhanced payouts apply if termination occurs within 12 months after a change in control (including pro‑rata/earned bonuses and full accelerated vesting).
• Board additions/independence: Troy Ignelzi (age 58), current CFO of Rapport Therapeutics (since Nov 2023) and former CFO at Karuna Therapeutics, was appointed to the Audit and Compensation Committees effective May 14, 2026 and was determined to be independent under Nasdaq/SEC rules.
• Resignations: Mr. Anastasiou’s and Mr. Gracias’ departures were stated as not due to any disagreement with the Company.

Why It Matters
These filings show a leadership shift: the company hired an experienced industry executive as COO with a compensation package that includes a significant equity award and severance protections—information investors use to assess management incentives and potential dilution from option grants. The board turnover (resignation and new independent director appointment) affects governance and committee composition, which may influence oversight of financial reporting and executive compensation. The 8-K provides the full employment agreement and formal disclosures for investors reviewing management changes and related costs.